# Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention

Study · id `cardio:ct-nct07536802` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07536802](<https://clinicaltrials.gov/study/NCT07536802>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07536802

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1148 participants.

## Technical summary

Registry record NCT07536802. Randomized; no masking; primary purpose treatment. Start 2025-06-01 (actual); primary completion 2026-05-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1148 participants (planned count; ClinicalTrials.gov record NCT07536802, source copy `cardio:ctgov-nct07536802-2026-04-22`, retrieved 2026-10-26)
- Started: 2025-06-01 (actual) (ClinicalTrials.gov record NCT07536802, source copy `cardio:ctgov-nct07536802-2026-04-22`, retrieved 2026-10-26)
- Primary completion: 2026-05-30 (anticipated) (ClinicalTrials.gov record NCT07536802, source copy `cardio:ctgov-nct07536802-2026-04-22`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT07536802, source copy `cardio:ctgov-nct07536802-2026-04-22`, retrieved 2026-10-26)
- Countries: Pakistan (ClinicalTrials.gov record NCT07536802, source copy `cardio:ctgov-nct07536802-2026-04-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07536802-2026-04-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention
- Acronym: AMPACT
- Condition: ST-Segment Elevation Myocardial Infarction (STEMI)
- Condition: No-Reflow Phenomenon
- Condition: Coronary Slow Flow
- Condition: Acute Myocardial Infarction
- Intervention (Drug): Adenosine pre-medication
- Intervention (Other): Standard care
- Lead sponsor: National Institute of Cardiovascular Diseases, Pakistan
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: National Institute of Cardiovascular Diseases, Pakistan (`cardio:org-national-institute-of-cardiovascular-diseases-pakistan`)

## Provenance

Content hash: c169d7a2e5502beffaab6bc9411f48dfc66f6d525b09b8574202aa3176ac8ab3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
